{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT03952078","orgStudyIdInfo":{"id":"CPI-818-001"},"organization":{"fullName":"Corvus Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma","officialTitle":"A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma"},"statusModule":{"statusVerifiedDate":"2025-04","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-05-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-04-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-05-07","studyFirstSubmitQcDate":"2019-05-14","studyFirstPostDateStruct":{"date":"2019-05-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-04-14","lastUpdatePostDateStruct":{"date":"2025-04-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Corvus Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.","detailedDescription":"This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts."},"conditionsModule":{"conditions":["T-cell Lymphoma"],"keywords":["CTCL","PTCL"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":151,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"CPI-818 Dose Escalation","type":"EXPERIMENTAL","description":"Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for \\>2 months or if dose determined to be unsafe.","interventionNames":["Drug: CPI-818"]},{"label":"CPI-818 Dose Expansion phase","type":"EXPERIMENTAL","description":"Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.\n\nCPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for \\> 2 months.","interventionNames":["Drug: CPI-818"]}],"interventions":[{"type":"DRUG","name":"CPI-818","description":"Interleukin-2 inducible T-cell Kinase Inhibitor","armGroupLabels":["CPI-818 Dose Escalation","CPI-818 Dose Expansion phase"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence, nature, and severity of adverse events following treatment with CPI 818 to establish the safety and tolerability with increasing dose","timeFrame":"First dose until 30 days after treatment stop"},{"measure":"Incidence and nature of dose limiting toxicities (DLTs) of CPI 818 to establish either the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of CPI 818","timeFrame":"Up to approximately 21 days after first dose"}],"secondaryOutcomes":[{"measure":"Area under the curve (AUC) of CPI-818 in blood samples to evaluate the pharmacokinetic profile of CPI 818","timeFrame":"Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days."},{"measure":"Maximum serum concentration (Cmax) of CPI-818 in blood samples to evaluate the pharmacokinetic profile of CPI 818","timeFrame":"Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days."},{"measure":"Objective response rate per Laguno Classification for CTCL and Consensus Statement for Response for CTCL to assess the anti-tumor activity of CPI 818 in subjects with R/R T cell lymphoma","timeFrame":"From start of treatment through end of study treatment, up to approximately 24 months"},{"measure":"Evaluate total percentage of tumor gene expression in post-treatment blood and tumor samples to evaluate pharmacodynamic changes with treatment.","timeFrame":"Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days."},{"measure":"Evaluate overall percentage of malignant cells in post-treatment blood and tumor samples to evaluate pharmacodynamic changes with treatment.","timeFrame":"Day 1, 2, 8, 15 of Cycle 1, Day 1 and 2 of Cycle 3, and Day 1 for all even number Cycles. Each Cycle is 21 days."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult subjects age ≥18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Histologically confirmed evidence of T-cell lymphoma\n* Measurable disease.\n* Adequate organ function.\n* At least 2 standard therapies for advanced or recurrent disease or had a disease for which there is no more than one established therapy.\n\nExclusion Criteria:\n\n* Treatment with systemic immunosuppressive medication.\n* History of allogeneic hematopoietic stem cell transplantation.\n* History of primary immunodeficiency, solid organ transplantation.\n* History of opportunistic infection within 180 days of starting study drug.\n* Females who are pregnant, lactating, or intend to become pregnant\n* History of invasive prior malignancy that required systemic therapy within last 3 years.\n* Concomitant use of strong inhibitors or inducers of CYP3A.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Suresh Mahabhashyam, MD, MPH","affiliation":"Corvus Pharmaceuticals","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Stanford University","city":"Palo Alto","state":"California","zip":"94304","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"University of Michigan","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Washington University","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Hackensack University Medical Center","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"Ohio State University","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"University of Pittsburgh","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Concord Repatriation General Hospital","city":"Concord","state":"New South Wales","zip":"2139","country":"Australia","geoPoint":{"lat":-33.84722,"lon":151.10381}},{"facility":"Liverpool Hospital","city":"Liverpool","state":"New South Wales","zip":"2170","country":"Australia","geoPoint":{"lat":-33.91938,"lon":150.92588}},{"facility":"Royal Adelaide Hospital","city":"Adelaide","state":"South Australia","zip":"5000","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Epworth Healthcare","city":"Melbourne","state":"Victoria","zip":"3002","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Beijing Friendship Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100052","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Boren Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Cancer Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Shanghai East Hospital","city":"Pudong","state":"Shanghai Municipality","zip":"200136","country":"China","geoPoint":{"lat":31.23995,"lon":121.50094}},{"facility":"Henan Cancer Hospital","city":"Henan","state":"Zhengzhou","zip":"450003","country":"China","geoPoint":{"lat":39.46731,"lon":115.13706}},{"facility":"Seoul National University Hospital","city":"Seoul","state":"Gyeonggido","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","state":"Gyeonggido","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","state":"Gyeonggido","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul St. Mary's Hospital","city":"Seoul","state":"Gyeonggido","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Inje University Busan-Paik Hospital","city":"Busan","zip":"47392","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Pusan National University Hospital","city":"Busan","zip":"49241","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Gachon University","city":"Incheon","zip":"21565","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D016399","term":"Lymphoma, T-Cell"}],"ancestors":[{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D008223","term":"Lymphoma"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06561048","orgStudyIdInfo":{"id":"CPI-818-004"},"organization":{"fullName":"Corvus Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","officialTitle":"A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma"},"statusModule":{"statusVerifiedDate":"2025-04","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-10-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-08-16","studyFirstSubmitQcDate":"2024-08-16","studyFirstPostDateStruct":{"date":"2024-08-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-04-15","lastUpdatePostDateStruct":{"date":"2025-04-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Corvus Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).","detailedDescription":"This is a Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib, an oral interleukin-2-inducible T cell kinase (ITK) inhibitor, versus physician's choice standard of care (SOC) treatment of either belinostat or pralatrexate in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL). Approximately 150 participants will be randomized at a 1:1 ratio to the 2 treatment arms (soquelitinib or SOC) and will be stratified by region of the world, age, and time to relapse for the most recent prior therapy. Participants will receive study treatment for up to a maximum of 2 years, unacceptable toxicity, or disease progression, whichever is earlier. Participants randomized to receive SOC who have confirmation of progressive disease may have the opportunity to crossover to receive treatment with soquelitinib."},"conditionsModule":{"conditions":["Peripheral T-Cell Lymphoma, Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Follicular T-Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Systemic Anaplastic Large Cell Lymphoma","Lymphoma, T-Cell, Peripheral","Lymphoma, T-Cell"],"keywords":["Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)","Follicular Helper T-Cell Lymphoma (FHTCL)","Angioimmunoblastic T-cell Lymphoma (AITL)","Follicular T-Cell Lymphoma (FTCL)","Nodal Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype (PTCL-Tfh)","Systemic Anaplastic Large Cell Lymphoma (sALCL)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Soquelitinib","type":"EXPERIMENTAL","description":"Participants will administer soquelitinib 200 mg orally twice daily for up to 2 years","interventionNames":["Drug: Soquelitinib"]},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","description":"Participants will receive physician's choice standard of care treatment of either pralatrexate or belinostat for up to 2 years","interventionNames":["Drug: Belinostat","Drug: Pralatrexate"]}],"interventions":[{"type":"DRUG","name":"Soquelitinib","description":"Soquelitinib 200 mg tablets will be taken by mouth two times a day","armGroupLabels":["Soquelitinib"],"otherNames":["CPI-818"]},{"type":"DRUG","name":"Belinostat","description":"Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle","armGroupLabels":["Standard of Care"],"otherNames":["Beleodaq®"]},{"type":"DRUG","name":"Pralatrexate","description":"Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle","armGroupLabels":["Standard of Care"],"otherNames":["Folotyn®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free survival","description":"Time from first study treatment to first occurrence of progression (as assessed by the Independent Review Committee) or death, whichever occurs first","timeFrame":"Up to 4 years post study treatment initiation"}],"secondaryOutcomes":[{"measure":"Objective response rate","description":"The rate of participants who achieve a partial response or complete response as assessed by the Independent Review Committee according to the Revised Criteria for Response Assessment of Malignant Lymphoma (Lugano Classification 2014), and modified Severity Weighted Assessment Tool (mSWAT) for participants with skin involvement","timeFrame":"Up to 2 years post study treatment initiation"},{"measure":"Overall survival","description":"Time from first study treatment to death from any cause","timeFrame":"Up to 4 years post study treatment initiation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adult participants ≥18 years of age on the day of signing the informed consent form.\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n3. Histologically confirmed PTCL-NOS, FHTCLs or sALCL per The International Consensus Classification of Mature Lymphoid Neoplasms.\n4. Progressed on, be refractory to, relapsed, or intolerant to standard therapy for their cancer. At least 1 but not more than 3 prior systemic therapies.\n5. Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease of at least 1.5 cm by computed tomography, as assessed by the site radiologist.\n6. Life expectancy \\>12 weeks.\n7. Adequate organ function as determined by:\n\n   * Absolute neutrophil count ≥ 1.0×10\\^9/L (1000/mm3) (without receiving granulocyte-colony stimulating factor)\n   * Platelet count ≥ 100×10\\^9/L (without transfusion)\n   * Hemoglobin ≥ 9.0 g/dL, without packed red blood cell transfusion within the last 1 week of starting study drug\n   * Prothrombin time international normalized ratio and partial thromboplastin time ≤1.5 × upper limit of normal (ULN), unless participant is receiving anticoagulant therapy and prothrombin time or activated partial thromboplastin time is within therapeutic range of intended use of anticoagulants\n   * Calculated creatinine clearance (CrCl) according to Cockcroft-Gault formula and based on ideal body weight or 24-hour urine CrCl ≥ 50 mL/minute\n   * Total bilirubin ≤ 1.5 × ULN or direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 × ULN. For participants with Gilbert's disease: ≤ 3.0 mg/dL or discussion with the Medical Monitor\n   * Aspartate aminotransferase and alanine transaminase ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases)\n   * Serum albumin \\> 2.5 g/dL\n   * Serum calcium \\< 12 mg/dL or corrected serum calcium \\< ULN\n8. Must have recovered from all AEs due to previous therapies to Grade ≤ 1 or baseline except for the following:\n\n   * Grade ≤ 2 neuropathy\n   * Alopecia and non-acute toxicities\n   * If major received major surgery, then must have recovered adequately per the investigator from the toxicity and/or complications from the intervention prior to starting study treatment\n9. Female participants of childbearing potential who are sexually active with a non-sterilized male partner must agree to use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 120 days after the last dose of study drug for participants who receive soquelitinib, or 6 months after the last dose for participants who receive either belinostat or pralatrexate.\n10. Non-sterilized males who are sexually active with a female partner of childbearing potential must use a condom plus spermicide from Day 1 through 120 days after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Participants who have T-cell lymphoma with active central nervous system involvement.\n2. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.\n3. History of primary immunodeficiency or sold organ transplantation.\n4. History of opportunistic infection within 30days of screening requiring active systemic treatment or active infection requiring IV therapy.\n5. Any active infection requiring IV therapy.\n6. History of invasive prior malignancy that required systemic therapy within last 3 years.\n7. Any condition that confounds the ability to interpret data from the study.\n8. Known to be positive for HIV, or positive test for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen \\[HBsAg\\]) or positive test for hepatitis C antibody.\n9. Monoclonal antibody therapy for cancer, radiotherapy, or chemotherapy within 3 weeks and targeted therapy within 2 weeks prior to the first dose of study treatment.\n10. Prior administration of an ITK inhibitor.\n11. Participants who need immediate cytoreductive therapy.\n12. Participants requiring the concomitant use of strong inhibitors or inducers of CYP3A or who have received these within 5 half-lives or 14 days prior to the start of study treatment.\n13. History of allogeneic hematopoietic stem cell transplantation.\n14. Candidate for hematopoietic stem cell transplantation at screening.\n15. History of progressive disease within 6 months of autologous hematopoietic stem cell transplantation.\n16. Concurrent enrollment in another clinical study\n17. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study, starting with the screening visit through 6 months after the last dose of study treatment.\n18. Participants who cannot ingest medications orally or who have malabsorption.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Study Director","role":"CONTACT","phone":"650-900-4520","email":"clinicaltrials@corvuspharma.com"}],"overallOfficials":[{"name":"Suresh Mahabhashyam, MD, MPH","affiliation":"Corvus Pharmaceuticals, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Corvus Pharmaceuticals","status":"RECRUITING","city":"South San Francisco","state":"California","zip":"94080","country":"United States","geoPoint":{"lat":37.65466,"lon":-122.40775}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D016399","term":"Lymphoma, T-Cell"},{"id":"D007119","term":"Immunoblastic Lymphadenopathy"},{"id":"D017728","term":"Lymphoma, Large-Cell, Anaplastic"},{"id":"D016411","term":"Lymphoma, T-Cell, Peripheral"}],"ancestors":[{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D008223","term":"Lymphoma"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D000072281","term":"Lymphadenopathy"}]},"interventionBrowseModule":{"meshes":[{"id":"C487081","term":"belinostat"},{"id":"C418863","term":"10-propargyl-10-deazaaminopterin"}]}},"hasResults":false}
]}